Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

Rhea-AI Summary

Viking Therapeutics, a clinical-stage biopharmaceutical company, will report its financial results for the first quarter of 2024 on April 24, 2024. The company will host a conference call to discuss the results and general corporate updates on the same day at 4:30 p.m. Eastern Time. Investors and analysts can participate in the call by dialing the provided numbers. A telephone replay will be available until May 1, 2024, and the conference call can also be accessed live via the internet.

Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time

SAN DIEGO, April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.

The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 24, 2024. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 1, 2024 by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #8359459. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts. An archive of the webcast will also be available on the Webcasts page of the company's website for 30 days.

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for obesity demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-first-quarter-2024-on-april-24-2024-302119720.html

SOURCE Viking Therapeutics, Inc.

FAQ

When will Viking Therapeutics report its financial results for the first quarter of 2024?

Viking Therapeutics will report its financial results for the first quarter of 2024 on April 24, 2024.

What time is the conference call scheduled for discussing the financial results and corporate updates?

The conference call for discussing the financial results and corporate updates is scheduled for 4:30 p.m. Eastern Time on April 24, 2024.

How can participants join the conference call?

Participants can join the conference call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S.

Until when will the telephone replay of the conference call be accessible?

The telephone replay of the conference call will be accessible until May 1, 2024.

Where can the conference call be accessed live via the internet?

The conference call can be accessed live via the internet by visiting the Webcasts page of Viking's website at http://ir.vikingtherapeutics.com/webcasts.